← Back to headlines
Zymeworks Maintains Market Outperform Stock Rating
Citizens Financial Group reiterates its bullish stance on biotech firm Zymeworks, maintaining a Market Outperform designation for investors.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
